Please login to the form below
Taflinar
This page shows the latest Taflinar news and features for those working in and with pharma, biotech and healthcare.
BMS gets two new cancer approvals in Europe
all patents regardless of their BRAF status, potentially making it more useful than BRAF inhibitors such as Roche's Zelboraf (vemurafenib) and Novartis' Taflinar (dabrafenib).
Latest news
-
BMS bags US approval for Opdivo and Yervoy combo
inhibitors such as Roche's Zelboraf (vemurafenib) and GSK's Taflinar (dabrafenib).
-
NICE backs GSK’s Tafinlar for skin cancer
NICE said the information provided by GSK suggested that Taflinar works as well as Zelboraf, which also targets the BRAF V600 mutations.
-
NICE fast-tracks GSK's skin cancer drug Tafinlar
However, just as Roche was forced to discount Zelboraf's price before NICE recommended it, the new Taflinar guidance was only issued on the basis GSK discount its drug's list ... Taflinar was approved in Europe in August 2013, based on phase III results
-
GSK's personalised cancer drug Tafinlar set for European approval
Regulatory advisors recommend the melanoma drug be licensed
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Medical Writer
-
Salary TBC
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Manager / Account Director
-
Competative
- Global Business Development Director – Health Education
-
excellent commission
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Associate Director
-
£75, 000-90, 000
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- AZ’s Sean Bohen to exit after business overhaul; report
- FDA moves into crisis mode as shutdown drags on
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
Latest intelligence
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Quick links
Infographics
